
Medicine Net Update 2025/07/10
On Jul 03, 2025, Norvatis announced results from the Phase III GCAptAIN study evaluating Cosentyx® (secukinumab) in adults with newly diagnosed or relapsing giant cell arteritis (GCA).
Updated on: July 16,2025
0

Medicine Net Update 2025/07/10
On Jul 03, 2025, Norvatis announced results from the Phase III GCAptAIN study evaluating Cosentyx® (secukinumab) in adults with newly diagnosed or relapsing giant cell arteritis (GCA).
Updated on:July 16,2025
0
